Please login to the form below

Not currently logged in
Email:
Password:

Pan

This page shows the latest Pan news and features for those working in and with pharma, biotech and healthcare.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Whilst Keytruda was the first therapy to be approved for pan-tumour use in 2017, its Microsatellite Instability-High or Mismatch Repair-Deficient indication differs from the NTRK TA therapies.

Latest news

More from news
Approximately 6 fully matching, plus 229 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 11 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 28 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....